CY1114005T1 - PEG-URINARY OXIDATIVE CONNECTORS AND USE OF THESE - Google Patents

PEG-URINARY OXIDATIVE CONNECTORS AND USE OF THESE

Info

Publication number
CY1114005T1
CY1114005T1 CY20131100416T CY131100416T CY1114005T1 CY 1114005 T1 CY1114005 T1 CY 1114005T1 CY 20131100416 T CY20131100416 T CY 20131100416T CY 131100416 T CY131100416 T CY 131100416T CY 1114005 T1 CY1114005 T1 CY 1114005T1
Authority
CY
Cyprus
Prior art keywords
peg
urinary
oxidative
connectors
poly
Prior art date
Application number
CY20131100416T
Other languages
Greek (el)
Inventor
L David Williams
Michael S Hershfield
Susan J Kelly
Mark G P Saifer
Merry R Sherman
Original Assignee
Mountain View Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09175303A external-priority patent/EP2158923B1/en
Application filed by Mountain View Pharmaceuticals Inc. filed Critical Mountain View Pharmaceuticals Inc.
Publication of CY1114005T1 publication Critical patent/CY1114005T1/en

Links

Landscapes

  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Μια φυσικά προκύπτουσα ή ανασυνδυασμένη ουρική οξειδάση (ουρικάση) ομοιοπολικά συνδεδεμένη με πολυ(αιθυλενική γλυκόλη) ή πολυ(αιθυλενικό οξείδιο) (και τα δύο αναφέρονται ως PEG), όπου ένας μέσος όρος 2 έως 10 κλώνων PEG είναι συζευγμένοι σε κάθε υπομονάδα ουρικάσης και η PEG έχει μέσο μοριακό βάρος μεταξύ 5kDa και l00kDa. Τα προκύπτοντα συζεύγματα PEG-ουρικάσης είναι ουσιαστικά μη ανοσοποιητικά και διατηρούν το 75% τουλάχιστον της ουρικολυτικής δραστικότητας του μη τροποποιημένου ενζύμου.A naturally occurring or recombinant urinary oxidase (uricase) covalently linked to poly (ethylene glycol) or poly (ethylene oxide) (both referred to as PEG), where an average of 2 to 10 PEG clones are conjugated to each urinary subunit and PEG has an average molecular weight between 5kDa and l00kDa. The resulting PEG-uricase conjugates are substantially non-immune and retain at least 75% of the uricolytic activity of the unmodified enzyme.

CY20131100416T 1998-08-06 2013-05-27 PEG-URINARY OXIDATIVE CONNECTORS AND USE OF THESE CY1114005T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21931898A 1998-08-06 1998-08-06
EP09175303A EP2158923B1 (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof

Publications (1)

Publication Number Publication Date
CY1114005T1 true CY1114005T1 (en) 2016-07-27

Family

ID=58448992

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100416T CY1114005T1 (en) 1998-08-06 2013-05-27 PEG-URINARY OXIDATIVE CONNECTORS AND USE OF THESE

Country Status (1)

Country Link
CY (1) CY1114005T1 (en)

Similar Documents

Publication Publication Date Title
CY1119848T1 (en) INSULATED TETRAMIC URINATION
NZ509595A (en) Peg-urate oxidase conjugates and use thereof
AU7761594A (en) Polyethylene glycols
WO2003055526A3 (en) Erythropoietin conjugates
AU2001296962A1 (en) Pegylated interleukin-10
DK0973819T3 (en) Non-antigenic branched polymer conjugates
DE69434448D1 (en) POLYMER PEPTIDE CONJUGATE
CA2323048A1 (en) Poly(ethylene glycol) derivatives with proximal reactive groups
PT1157037E (en) GCSF CONJUGATES
WO2003040211A3 (en) Branched polymers and their conjugates
CY1106886T1 (en) NEUBLASTIN POLYMER COGNITION PRODUCTS AND METHODS OF USE
CY1114005T1 (en) PEG-URINARY OXIDATIVE CONNECTORS AND USE OF THESE
AU2003285286A1 (en) Conjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol)